Table 1 Baseline characteristics of patients in each group.
From: Real-world retention rates of biologics in patients with rheumatoid arthritis
ABT | TCZ | IFX | ETN | ADA | GLM | CZP | p-value | |
|---|---|---|---|---|---|---|---|---|
Cases (no.) | 67 | 84 | 74 | 224 | 86 | 44 | 25 | |
Age (years) | 69.1 ± 11.8 | 60.8 ± 15.3 | 51.6 ± 12.8 | 59.9 ± 16.1 | 61.9 ± 14.1 | 67.2 ± 9.75 | 61.2 ± 13.9 | < 0.0001 |
Male rate (%) | 23.9 | 20.2 | 32.4 | 16.5 | 18.6 | 18.2 | 20 | 0.1475 |
Body weight (kg) | 54.8 ± 14.4 | 55.5 ± 11.5 | 58.4 ± 12.8 | 53.9 ± 11.5 | 54.4 ± 12.1 | 55.2 ± 13.5 | 55.6 ± 12.5 | 0.2771 |
BMI | 22.7 ± 4.2 | 22.6 ± 3.9 | 22.5 ± 3.7 | 21.9 ± 3.7 | 22.1 ± 3.6 | 23.2 ± 4.8 | 22.5 ± 3.5 | 0.4376 |
Order of biologic use (no.) | 2 | 2.3 | 1.1 | 1.2 | 1.7 | 2 | 2 | < 0.0001 |
Biologic naïve patients (%) | 52.2 | 21.4 | 95.9 | 81.7 | 46.5 | 50.0 | 36.0 | < 0.0001 |
ACPA positivity (%) | 89.6 | 97.6 | 90.5 | 88.2 | 87.1 | 88.6 | 92 | 0.3094 |
RF positivity (%) | 82.1 | 86.9 | 82.2 | 78.5 | 75.6 | 81.8 | 76 | 0.5908 |
PSL usage (%) | 61.2 | 61.9 | 71.8 | 63.8 | 60 | 65.9 | 48 | 0.3755 |
MTX usage (%) | 70.1 | 67.9 | 98.6 | 72.9 | 82.6 | 93.2 | 80 | < 0.0001 |
PSL dose (mg/day) | 4.4 ± 2.7 | 5.2 ± 2.6 | 5.9 ± 2.8 | 5.4 ± 3.0 | 4.4 ± 2.2 | 4.5 ± 2.2 | 4.6 ± 2.0 | 0.0116 |
MTX dose (mg/week) | 7.6 ± 3.7 | 8.5 ± 3.9 | 7.7 ± 2.6 | 6.9 ± 2.7 | 8.3 ± 3.9 | 7.6 ± 3.9 | 10.2 ± 3.8 | < 0.0001 |
